[TP53 mutations and molecular epidemiology]
- PMID: 17496437
[TP53 mutations and molecular epidemiology]
Abstract
Tumor suppressor p53 protein is activated by a variety of cellular stresses through several pathways and transactivates its downstream genes, including regulators of cell cycle, apoptosis and DNA repair. The loss of p53 function by TP53 gene mutations therefore fails to activate these genes and is thought to be a critical cause of carcinogenesis and/or tumor progression. TP53 is one of the most frequently mutated genes in human cancer. TP53 mutations are found in about 50% of human cancers, although the frequency of TP53 mutations differs among tumor types. However, the degree of functional disorder of mutant p53 varies according to the type of TP53 mutation. And the effects of p53 on cancer formation and/or progression are influenced by the degree of p53 dysfunction. So it is important to analyze the effects of TP53 mutations carefully according to the oncogenicity of each mutation from the molecular epidemiological point of view. Here, together with some cautions needed for analyzing and interpreting the significance of TP53 gene mutations, we present some examples of the identified specific mutation spectrum and the correlation between the prognosis and TP53 mutation in some cancers.
Similar articles
-
The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer.J Urol. 2003 Apr;169(4):1219-28. doi: 10.1097/01.ju.0000056085.58221.80. J Urol. 2003. PMID: 12629332 Review.
-
Tissue polypeptide antigen (TPA) in comparison with mutations of tumour suppressor gene P53 (TP53) in patients with bladder cancer.Anticancer Res. 2003 Mar-Apr;23(2A):957-62. Anticancer Res. 2003. PMID: 12820330
-
TP53 tumour suppressor gene: clues to molecular carcinogenesis and cancer therapy.Cancer Surv. 1996;28:169-96. Cancer Surv. 1996. PMID: 8977035 Review.
-
TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes.Oncogene. 2007 Apr 2;26(15):2157-65. doi: 10.1038/sj.onc.1210302. Oncogene. 2007. PMID: 17401424 Review.
-
P53 mutation analysis of colorectal liver metastases: relation to actual survival, angiogenic status, and p53 overexpression.Clin Cancer Res. 2005 Jun 1;11(11):4067-73. doi: 10.1158/1078-0432.CCR-04-2389. Clin Cancer Res. 2005. PMID: 15930341
Cited by
-
LIN28B inhibition sensitizes cells to p53-restoring PPI therapy through unleashed translational suppression.Oncogenesis. 2022 Jul 2;11(1):37. doi: 10.1038/s41389-022-00412-8. Oncogenesis. 2022. PMID: 35780125 Free PMC article.
-
Heterochronic triple primary malignancies with Epstein-Barr virus infection and tumor protein 53 gene mutation: A case report and review of literature.World J Clin Cases. 2021 Feb 16;9(5):1184-1195. doi: 10.12998/wjcc.v9.i5.1184. World J Clin Cases. 2021. PMID: 33644183 Free PMC article.
-
Exposure to depleted uranium does not alter the co-expression of HER-2/neu and p53 in breast cancer patients.BMC Res Notes. 2011 Mar 29;4:87. doi: 10.1186/1756-0500-4-87. BMC Res Notes. 2011. PMID: 21443808 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous